|
WO2015082520A1
|
|
Composition for reducing skin ageing disorders, comprising a retinaldehyde and a leontopodium alpinum extract
|
|
FR3013984A1
|
|
TOPICAL COMPOSITION COMPRISING AT LEAST ONE EXTRACT OF MATRICARIA RECUTITA WITH AT LEAST ONE HIGHLY POLYMERIZED DNA, AND USES THEREOF
|
|
WO2005011642A1
|
|
Single unit pharmaceutical composition comprising a mixture of a fibrate and an homocysteine reducing agent
|
|
WO2005117838A1
|
|
Stable oral pharmaceutical compositions of buprenorphine and derivatives
|
|
CA2519228A1
|
|
Improved dry powder inhaler system
|
|
EP1658063A1
|
|
Advantageous combinations for inhalation of nacystelyn and bronchodilators
|
|
CA2534910A1
|
|
Stable controlled release pharmaceutical compositions containing fenofibrate and pravastatin
|
|
CA2456732A1
|
|
Oral pharmaceutical composition containing a combination of ppar.alpha. and a hmg-coa reductase inhibitor
|
|
CA2456721A1
|
|
Pharmaceutical composition comprising salmeterol and budesonide for the treatment of respiratory disorders
|
|
CA2450238A1
|
|
Oral pharmaceutical composition containing a statin derivative
|
|
CA2423172A1
|
|
Sustained release composition containing clarithromycin
|
|
EP1318791A1
|
|
Pharmaceutical semi-solid composition of isotretinoin
|
|
WO03013607A1
|
|
ORAL PHARMACEUTICAL COMPOSITION CONTAINING A COMBINATION OF FENOFIBRATE AND A HMG-CoA REDUCTASE INHIBITOR
|
|
AU1121301A
|
|
Stable oral formulation containing benzimidazole derivative
|
